Patents by Inventor Paul Holvoet

Paul Holvoet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10704097
    Abstract: The present invention relates to diagnosis and/or prognosis of cardiovascular disease and cardiovascular events. A prognostic risk score in relation to the cardiovascular events, more particular after intervention, can be determined by counting the number of deregulated genes (or derived proteins) in their isolated monocytes. Deregulation means low expression of COX1 and/or COX4I1, and/or TFAM, and/or RUNX2.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: July 7, 2020
    Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Paul Holvoet, Stefan Janssens, Peter Sinnaeve
  • Publication number: 20170016071
    Abstract: The present invention relates to diagnosis and/or prognosis of cardiovascular disease and cardiovascular events. A prognostic risk score in relation to the cardiovascular events, more particular after intervention, can be determined by counting the number of deregulated genes (or derived proteins) in their isolated monocytes. Deregulation means low expression of COX1 and/or COX4I1, and/or TFAM, and/or RUNX2.
    Type: Application
    Filed: August 26, 2016
    Publication date: January 19, 2017
    Inventors: Paul HOLVOET, Stefan JANSSENS, Peter SINNAEVE
  • Publication number: 20110053167
    Abstract: The present invention relates generally to a new cluster of correlating molecules in a tissue or at least one cell of a tissue for instance a cell of a blood tissue, preferably such myeloid cells and of identifying the condition of the genes expression said correlating molecules or of the expression levels of said molecules in a method or system for identifying obesity and the risk at obesity-related metabolic diseases such as the obesity associated cardiovascular risk or obesity-related insulin resistance. This system of method provides information on how to modulate the correlating molecules to treat or prevent obesity and to prevent the obesity-related metabolic diseases.
    Type: Application
    Filed: April 2, 2009
    Publication date: March 3, 2011
    Applicant: Katholieke Universiteit Leuven
    Inventors: Paul Holvoet, Nora Benhabiles, Benjamine Geeraert
  • Publication number: 20100099640
    Abstract: The present invention provides isolated or essentially pure diterpenoic tetrahydropyran, such as steviol-19-glucuronide, steviol, stevioside and rebaudioside processes for obtaining the same and methods for obtaining stable pharmaceutically acceptable salts of the same for use of such compounds or compositions in a treatment of cardiovascular disorders or vascular disease or for the manufacture of medicaments to treat a condition of a cardiovascular disorder or vascular disease.
    Type: Application
    Filed: May 5, 2008
    Publication date: April 22, 2010
    Inventors: Joannes Geuns, Paul Holvoet
  • Publication number: 20080033150
    Abstract: Immunoassays for malondialdehyde-modified low density lipoprotein (MDA-modified LDL) and oxidized low density lipoprotein (OxLDL), monoclonal antibodies (and the cell lines for them) for use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control) are disclosed. MDA-modified LDL and OxLDL are implicated in atherosclerosis and its etiology.
    Type: Application
    Filed: May 7, 2007
    Publication date: February 7, 2008
    Inventors: Paul Holvoet, Desire Collen
  • Publication number: 20070259388
    Abstract: Immunoassays for malondialdehyde-modified low density lipoprotein (MDA-modified LDL) and oxidized low density lipoprotein (OxLDL), monoclonal antibodies (and the cell lines for them) for use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control) are disclosed. MDA-modified LDL and OxLDL are implicated in atherosclerosis and its etiology.
    Type: Application
    Filed: June 12, 2007
    Publication date: November 8, 2007
    Inventors: Paul Holvoet, Desire Collen
  • Publication number: 20070249006
    Abstract: Immunoassays for malondialdehyde-modified low density lipoprotein (MDA-modified LDL) and oxidized low density lipoprotein (OxLDL), monoclonal antibodies (and the cell lines for them) for use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control) are disclosed. MDA-modified LDL and OxLDL are implicated in atherosclerosis and its etiology.
    Type: Application
    Filed: May 11, 2007
    Publication date: October 25, 2007
    Inventors: Paul Holvoet, Desire Collen
  • Publication number: 20070190586
    Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.
    Type: Application
    Filed: January 16, 2007
    Publication date: August 16, 2007
    Inventors: Paul Holvoet, Desire Collen
  • Publication number: 20050084917
    Abstract: Immunoassays for malondialdehyde-modified low density lipoprotein (MDA-modified LDL) and oxidized low density lipoprotein (OxLDL), monoclonal antibodies (and the cell lines for them) for use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control) are disclosed. MDA-modified LDL and OxLDL are implicated in atherosclerosis and its etiology.
    Type: Application
    Filed: March 17, 2004
    Publication date: April 21, 2005
    Inventors: Paul Holvoet, Desire Collen